Our top pick for
Provention Bio, Inc is a biotechnology business based in the US. Provention Bio shares (PRVB) are listed on the NASDAQ and all prices are listed in US Dollars. Provention Bio employs 19 staff and has a market cap (total outstanding shares value) of USD$885.2 million.
|Latest market close||USD$16.53|
|52-week range||USD$4.72 - USD$18.5|
|50-day moving average||USD$13.7697|
|200-day moving average||USD$13.406|
|Wall St. target price||USD$28.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.943|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-6.08%|
|1 month (2020-12-16)||-10.02%|
|3 months (2020-10-15)||23.82%|
|6 months (2020-07-15)||30.98%|
|1 year (2020-01-15)||7.48%|
|2 years (2019-01-15)||661.75%|
|3 years (2018-01-15)||N/A|
|5 years (2016-01-15)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-39.26%|
|Return on equity TTM||-67.5%|
|Market capitalisation||USD$885.2 million|
TTM: trailing 12 months
There are currently 3.5 million Provention Bio shares held short by investors – that's known as Provention Bio's "short interest". This figure is 4.1% down from 3.6 million last month.
There are a few different ways that this level of interest in shorting Provention Bio shares can be evaluated.
Provention Bio's "short interest ratio" (SIR) is the quantity of Provention Bio shares currently shorted divided by the average quantity of Provention Bio shares traded daily (recently around 453912.94117647). Provention Bio's SIR currently stands at 7.65. In other words for every 100,000 Provention Bio shares traded daily on the market, roughly 7650 shares are currently held short.
However Provention Bio's short interest can also be evaluated against the total number of Provention Bio shares, or, against the total number of tradable Provention Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Provention Bio's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Provention Bio shares in existence, roughly 60 shares are currently held short) or 0.0678% of the tradable shares (for every 100,000 tradable Provention Bio shares, roughly 68 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Provention Bio.
Find out more about how you can short Provention Bio stock.
We're not expecting Provention Bio to pay a dividend over the next 12 months.
Over the last 12 months, Provention Bio's shares have ranged in value from as little as $4.72 up to $18.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Provention Bio's is 3.554. This would suggest that Provention Bio's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.